Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 4/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.49 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4014512 | 1.00 | ALK (0.57) | ALKCHEK1FLT3MEN1KMT2A | |
| SCHEMBL4013829 | 0.84 | MEN1 (0.60) | ALKCHEK1FLT3MEN1KMT2A | |
| SCHEMBL4013834 | 0.84 | MEN1 (0.60) | ALKCHEK1FLT3MEN1KMT2A | |
| SCHEMBL4021592 | 0.82 | CHEK1 (0.62) | ALKCHEK1FLT3MEN1KMT2A | |
| SCHEMBL4021596 | 0.82 | CHEK1 (0.62) | ALKCHEK1FLT3MEN1KMT2A | |
| SCHEMBL4015690 | 0.81 | FLT3 (0.50) | ALKFLT3MEN1KMT2ACDK2 | |
| SCHEMBL4015685 | 0.81 | FLT3 (0.50) | ALKFLT3MEN1KMT2ACDK2 | |
| SCHEMBL4021638 | 0.80 | ALK (0.54) | ALKFLT3MEN1KMT2ACDK2 | |
| SCHEMBL4021631 | 0.80 | ALK (0.54) | ALKFLT3MEN1KMT2ACDK2 | |
| SCHEMBL4019531 | 0.79 | CHEK1 (0.68) | ALKCHEK1FLT3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009085040-A1 | PROTEIN KINASE INHIBITORS | DCB-USA LLC (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163494-A1 | PROTEIN KINASE INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163494-A1 | PROTEIN KINASE INHIBITORS | BRAF, MAP3K20, SELENOI | ALK 2146/4885CHEK1 120/4885FLT3 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.